Search Results 5971-5980 of 24930 for oral
oral TNG908 6. Active prior or concurrent malignancy. 7. Central nervous system metastases associated with progressive neurological symptoms 8. Current ...
Able to swallow oral medication. Key Exclusion Criteria: 1. Patients with uveal or mucosal melanoma 2. Prior therapy with an ERK-, MEK-, RAF-, or RAS ...
After 6 cycles, maintenance rituximab may be administered per physician discretion. Venetoclax is an oral Bcl-2 family protein inhibitor. It targets the B-cell ...
... Oral and throat cancer, Laryngeal cancer, Salivary gland cancer, Oropharyngeal cancer, Hypopharyngeal cancer. Show more areas of focus for Homan Mohammadi ...
Simulated comparison of topical and oral formulations of 5-aminosalicylate for the treatment of ulcerative colitis. Inflamm Bowel Dis. 2013 Feb; 19 (2):301 ...
Able to swallow oral suspension drugs. Able to ambulate without the assistance of another person, defined as ability to walk at least 10 meters. Use of ...
Investigating tumor growth factors for oral cancer. Evaluating new methods of use for chemotherapy. Evaluating new radiation therapy regimens. Investigating ...
WOCBP taking oral contraceptives (OCs) also have to use one barrier method. Exclusion Criteria: 1. Prebronchodilator Forced Expiratory Volume in 1 second ...
Research at Mayo Clinic in diabetic nephropathy includes developing new diagnostic and treatment tools, such as oral medicines that may help stop or delay ...
... oral contraceptive pill or transdermal patch, spermicide and barrier [condoms], intrauterine device, implants for contraception, injections for ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Make a gift before July 31 and it can be doubled in impact thanks to a $100,000 Summer Challenge.